NEW YORK (GenomeWeb News) - Linguamatics, a provider of natural language processing technology, said today that it has extended an existing collaboration with Pfizer.
Under the terms of the extended agreement, Pfizer will use Linguatmatics' I2E text-mining software within its Biotherapeutics and Bioinnovation Center, a new “entrepreneurial” R&D center that the company created last fall with the goal of advancing translational research via internal development as well as in-licensing and incubating new technologies and research tools.
Financial details of the agreement were not disclosed.
David de Graaf, director of systems biology at Pfizer, said in a statement that the company was previously using I2E “for focused knowledge discovery from large document collections in a variety of R&D applications.”
Under the extended agreement, he said, Pfizer is using the platform “to inform research decisions” within the Biotherapeutics and Bioinnovation Center.